INTS — INTENSITY THERAPEUTICS, INC.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1567264 ·
Last close
$2.67
Market Cap
$8.81M
52W High
$15.00
52W Low
$2.59
ADV30
19,611
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | — | — | — | — | — | — | — |
| Jun 2026 | 0 | — | -3,084,000 | -3,007,000 | 11,521,000 | 9,529,000 | 2,307,000 |
| Mar 2026 | 0 | — | -2,526,000 | -2,434,000 | 12,291,000 | 10,245,000 | 2,312,000 |
| Dec 2025 | 0 | — | -3,140,000 | -3,051,000 | 14,101,000 | 11,921,000 | 2,225,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,954,000
Investing CF
$0
Financing CF
$16,267,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.93
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-83,830,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-11,483,000
Pretax Income TTM
$-11,163,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -11,972,000 | -11,606,000 | 14,101,000 | 2,225,000 | 11,876,000 | -9,233,000 |
| Dec 2024 | 0 | -16,585,000 | -16,268,000 | 4,783,000 | 1,865,000 | 2,918,000 | -15,220,000 |
| Dec 2023 | 0 | -8,319,000 | -10,538,000 | 17,295,000 | 4,133,000 | 13,162,000 | -7,205,000 |
| Dec 2022 | 0 | -7,550,000 | -7,582,000 | 1,757,000 | 16,855,000 | -15,098,000 | -5,477,000 |
TTM Snapshot
Revenues TTM
$319,000
NetIncome TTM
$-11,163,000
OpCashFlow TTM
—
Assets (Latest)
$11,521,000
Forward EPS
$-1.99
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INAB | IN8BIO, INC. | $8.86M | $0.82 | — |
| TCRX | TScan Therapeutics, Inc. | $9.59M | $0.15 | — |
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | $9.72M | $0.88 | — |
| CUBT | Curative Biotechnology Inc | $7.56M | $0.85 | — |
| ALGS | Aligos Therapeutics, Inc. | $7.40M | $1.36 | — |
News headlines (Yahoo Finance, 1h cache)
Intensity (INTS) Q3 2026 Earnings Call Transcript
2026-11-05 22:28 · Yahoo
Intensity Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-05 12:45 · Yahoo
Intensity Therapeutics to Announce Third Quarter 2026 Financial Results on November 5, 2026
2026-10-30 12:00 · Yahoo
Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentatio
2026-10-23 12:00 · Yahoo
Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:00 · Yahoo
Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript
2026-08-12 01:57 · Yahoo
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026
2026-08-04 12:00 · Yahoo
Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
2026-07-01 12:00 · Yahoo
Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
2026-05-01 13:55 · Yahoo
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
2026-05-14 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.